

Effects of Bacopa monnieri herbal supplement on aging and neurocognitive functions with relation to constitution (Prakriti) in healthy adults

Submission date 22/01/2025	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 28/01/2025	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 18/07/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Aging is an irreversible process influenced by both internal (genetic) and external (environmental) factors. These factors contribute to differences in how individuals age. Aging is not just about a decline in physical and mental abilities but involves complex biological mechanisms. Aging can be explained through two main theories: 1. Programmed Theories: Suggest that aging follows a biological clock; and, 2. Error Theories: Propose that aging is caused by environmental damage to cells, leading to DNA damage and the accumulation of harmful substances. One key factor in aging is telomere shortening. Telomeres are protective caps at the ends of chromosomes that shorten with each cell division. When they become too short, cells stop dividing, a process known as cellular senescence. Telomere length is maintained by an enzyme called telomerase, but its activity decreases with age. Aging is also associated with changes in the brain, including a decline in cognitive abilities like memory and decision-making. These changes can be observed through brain activity using techniques like EEG (electroencephalography). This study aims to explore whether an Ayurvedic herbal decoction can help slow aging-related changes, maintain telomere length, and improve cognitive functions.

Who can participate?

Healthy males and females aged 60 to 64 years with a Montreal Cognitive Assessment (MoCA) score of 24 or above

What does the study involve?

Participants will be randomly divided into two groups: one group will receive a herbal decoction (BMFD), and the other group will receive a placebo (a substance with no active ingredients). The study will last 90 days (45 days of treatment followed by 45 days of observation). Assessments will be conducted before treatment begins, after 45 days of treatment, and after 45 days of follow-up.

What are the possible benefits and risks of participating?

There are many possible benefits of being part of clinical research, including:

- Participants may have the chance to help the research group better understand their disease or condition and to advance treatments and ways to prevent it in the future.
- Participants may feel like playing a more active role in their health.
- Participants may learn more about their disease or condition.
- Participants may be able to get information about support groups and resources.

Compared with risk, the benefits are much less because the total study protocol assesses and screens the health status of the participants and it could lead to early detection of the cognitive impairment and total assessment of the health condition of the entire nerve system by nerve conduction test and electroencephalography.

These studies do come with some possible risks, including:

- The research may involve tests that pose a risk to participants. For example, certain physical tests (blood withdrawal) may increase the chance of contamination and physical discomfort.
- Participating in a study could also be inconvenient for participants for example may be required to have additional or longer medical appointments, more procedures, and complex investigation instructions, as given below would be followed in taking the measurements. Hematological and biochemical investigations will be assessed at baseline.

Where is the study run from?

The University of Colombo

When is the study starting and how long is it expected to run for?

May 2023 to April 2027

Who is funding the study?

The University of Colombo

Who is the main contact?

1. Dr H.L.N.R. Pradeep, Department of Basic Principles and Ayurveda Anatomy, Faculty of Indigenous Medicine, University of Colombo, ranganapradeep@fim.cmb.ac.lk
2. Prof Pathirage Kamal Perera, Faculty of Indigenous Medicine, University of Colombo, kamalperera@fim.cmb.ac.lk

Contact information

Type(s)

Principal Investigator

Contact name

Dr Hewa Loku Nakathige Rangana Pradeep

ORCID ID

<https://orcid.org/0009-0004-5186-5706>

Contact details

Faculty of Indigenous Medicine
University of Colombo
Colombo
Sri Lanka

0094
+94 (0)711723283
ranganapradeep@fim.cmb.ac.lk

Type(s)

Public

Contact name

Prof Pathirage Kamal Perera

ORCID ID

<https://orcid.org/0000-0003-0337-1336>

Contact details

Faculty of Indigenous Medicine
University of Colombo
Colombo
Sri Lanka
0094
+94 (0)716419072
kamalperera@fim.cmb.ac.lk

Type(s)

Scientific

Contact name

Prof Dilshani Dissanyake

ORCID ID

<https://orcid.org/0000-0001-6859-2397>

Contact details

Department of Physiology
Faculty of Medicine
University of Colombo
Colombo
Sri Lanka
0094
+94 (0)718232420
dilshanid@physiol.cmb.ac.lk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

University of Colombo Research Grant No. AP/3/2/2024/SG/10

Study information

Scientific Title

Influence of Bacopa monnieri on telomerase activity, telomere length and aging- related changes and cognitive functions with relation to prakriti (constitution) of healthy adults

Acronym

BACOGENIC Study

Study objectives

The BMFD -Bacopa monnieri (L) Wettst freeze-dried decoction, dosage form, which demonstrates the highest anti-aging and anti-lipase activities, is hypothesized to be more effective in stabilizing the aging process and improving aging-related cognitive functions compared to a placebo.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 16/11/2023, Ethics Review Committee Faculty of indigenous Medicine University of Colombo (ERCFIM) (Faculty of Indigenous Medicine University of Colombo, Colombo, +94, Sri Lanka; +94- 11-2692385 Ext- 112; ethicsreviewiim@gmail.com), ref: ERC 23/202

Study design

Single-center parallel-assignment two-arm open-label non-inferiority randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Care home, Community, University/medical school/dental school

Study type(s)

Quality of life, Treatment, Safety

Participant information sheet

See study outputs table

Health condition(s) or problem(s) studied

The healthcare domain being studied is healthy aging and cognitive function enhancement, with a focus on the influence of Bacopa monnieri (L) Wettst on telomerase activity, telomere length, and prakriti (constitution) of healthy adults.

Interventions

This will be a two-arm, open-label, non-inferiority randomized control trial in patients with cognitive impairment. A consecutive consenting sample method will be followed to select participants of the arms for the study. A blocked design will be used, using an online statistical computing web programming to generate the randomization schedule (research randomizer <https://www.randomizer.org>). Eligible subjects will be randomly assigned to Arm I and Arm II to receive herbal decoction (BMFD-Bacopa monnieri (L) Wettst freeze-dried decoction) and placebo. Participants will be informed to put the supplied herbal pack (60 g of BMFD) into a pot, add 1920 ml of water, and simmer under a low flame until the volume is reduced to 240 ml. The process of preparation under standard conditions will be demonstrated to patients who are selected for the BMFD Arm (Arm I) at the Neuroscience Research Centre, Department of Physiology, Faculty of Medicine, University of Colombo, Sri Lanka and Clinical trial Unit, Faculty of Indigenous Medicine, University of Colombo, Sri Lanka using a video. Consenting participants who meet the inclusion criteria undergo a general physical checkup by the PI. Participants with chronic and acute disorders will be excluded. Those selected for the study will be coded, and those undergoing Stage of BMFD dosage form or placebo (Arm II) will be given. The duration of the BMFD dosage form or placebo administration will be 45 days. It will be given as 120 ML twice a day. They will be requested to take a daily dose of 120 ml twice a day before meals. The total duration of BMFD administration is 45 days. Follow-up duration: 45 days.

Intervention Type

Supplement

Primary outcome measure

The following primary outcome measures are assessed at baseline, 45 and 90 days:

1. Cognitive impairment will be measured using the Montreal Cognitive Assessment (MoCA) validated for the Sri Lankan population
2. Telomerase activity and telomerase length of blood mononuclear cells of participants measured using qualitative polymerase chain reaction (QPCR)
3. Median nerve and Ulnar for upper limb function and Tibial and Common peroneal nerve for lower limb function measured using the nerve conduction test (NCT)
4. Electrical activity of the brain measured using electroencephalography (EEG)

Secondary outcome measures

Health-related quality of life (HRQoL) measured using an HRQoL questionnaire (Janković, Slobodan M., et al. 2021) at baseline and the end of the intervention (after 45 days, 90 days of follow-up)

Overall study start date

11/05/2023

Completion date

18/04/2027

Eligibility

Key inclusion criteria

Current inclusion criteria as of 13/03/2025:

1. Healthy individuals aged 60 - 64 years
2. Both males and females
3. Nonsmokers and non-alcoholic
4. The MoCA score is 24 or above

Previous inclusion criteria:

1. Healthy individuals aged 60 - 64 years
2. Both males and females
3. Nonsmokers and non-alcoholic
4. The MoCA score ranges between 0-30 and a score of 24 or above

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

60 Years

Upper age limit

64 Years

Sex

Both

Target number of participants

37 patients for each arm

Key exclusion criteria

1. Healthy individuals below 60 and above 64 years
2. Individuals between 60 to 64 years old with CKD, CVD, Liver disorders, psychiatric illnesses, DM, cancers, Hypertension, hyperlipidemia etc
3. Those who have medically diagnosed diseases with reduced capacity to answer questions

Added 18/07/2025:

4. Participants with dyspeptic symptoms

Date of first enrolment

18/05/2025

Date of final enrolment

18/11/2025

Locations

Countries of recruitment

Sri Lanka

Study participating centre

Neuroscience Research Center, Faculty of Medicine and Faculty of Indigenous Medicine,
University of Colombo

The Faculty of Medicine and Faculty of Indigenous Medicine, University of Colombo

No. 25, Kynsey Road
Colombo
Sri Lanka
00800

Sponsor information

Organisation

University of Colombo

Sponsor details

College House
94, Cumaratunga Munidasa Mawatta
Colombo 03
Colombo
Sri Lanka
0094
+94 112 581 835
dean@fim.cmb.ac.lk

Sponsor type

University/education

Website

<https://med.cmb.ac.lk/>

ROR

<https://ror.org/02phn5242>

Funder(s)

Funder type

University/education

Funder Name

University of Colombo

Alternative Name(s)

University of Colombo, Sri Lanka, UoC

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location
Sri Lanka

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal. Additional documents will be available upon request from Dr H.L.N. Rangana Pradeep (ranganapradeep@fim.cmb.ac.lk). The study protocol is planned to be published in a peer-reviewed indexed journal.

Intention to publish date

30/12/2026

Individual participant data (IPD) sharing plan

The datasets generated during and/or analyzed during the current study are/will be available upon request from Dr H.L.N. Rangana Pradeep (ranganapradeep@fim.cmb.ac.lk). Study participant data sheets will not include contact or identifying details. Study data entry and study management systems used by clinical sites will be secured and password protected. At the end of the study, all study databases will be de-identified and archived. The availability of raw data for the study is based on the above conditions.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet			24/01/2025	No	Yes